BiotechTube

ICL670

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

Conditions

Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

Trial Timeline

Sep 1, 2013 โ†’ Oct 1, 2015

NCT ID
NCT01610297

About ICL670

ICL670 is a approved stage product being developed by Novartis for Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major. The current trial status is completed. This product is registered under clinical trial identifier NCT01610297. Target conditions include Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT01610297ApprovedCompleted
NCT01090323Phase 2Completed
NCT01044186Phase 2Completed

Competing Products

20 competing products in Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

See all competitors
ProductCompanyStageHype Score
KER-047Keros TherapeuticsPhase 2
44
H. pylori treatmentEisaiPhase 2/3
65
DeferasiroxNovartisPhase 3
77
CSJ137 + PlaceboNovartisPhase 1
33
Deferasirox and DeferoxamineNovartisPhase 2
52
DeferasiroxNovartisPhase 2
52
ICL670NovartisPhase 2
52
DeferasiroxNovartisApproved
85
Deferasirox + DeferasiroxNovartisPhase 2/3
65
DesferasiroxNovartisApproved
85
DeferasiroxNovartisPhase 2
52
DeferasiroxNovartisPhase 3
77
Deferasirox dispersible tablet + Defearisox film-coated tabletNovartisPhase 2
52
deferasiroxNovartisApproved
85
Deferasirox (ICL670)NovartisPhase 1/2
41
DeferasiroxNovartisPhase 3
77
Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + DeferoxamineNovartisPhase 2
52
DeferasiroxNovartisApproved
85
Z-213 + Saccharated Ferric OxideZeria PharmaceuticalPhase 3
76
Z-213Zeria PharmaceuticalPhase 3
76

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85